Health And Medicine

Gastrointestinal inflammation, such as occurs in inflammatory bowel disease, triggers the expansion of a population of “bone-eating” cells, leading to bone loss. Read More

Researchers at Vanderbilt University Medical Center have discovered why the uropathogenic bacterium E. coli, the leading cause of urinary tract infections, is so tenacious; their findings could lead to new ways to prevent recurrent UTIs. Read More

A Vanderbilt research team has discovered that activation of a certain protein complex involved in the inflammatory response in immune cells contributes to salt-sensitive hypertension. Read More

A Thursday, Aug. 25, discussion will connect how childhood trauma impacts brain development and behavior, its intersection with the justice system, and how we can integrate this understanding in prevention, diversion and restorative efforts.   Read More

Vanderbilt study of 18,130 telehealth visits at the beginning of the COVID-19 pandemic defines risk factors associated with telehealth access and suggests how health systems can improve access. Read More

Just one-third of patients with relapsing multiple sclerosis remain on disease-modifying therapy, and specialty pharmacists are in a unique position to help coordinate therapy discontinuation or change and reduce the risk of relapse. Read More

A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer. Read More

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers. Read More

Researchers at Vanderbilt University Medical Center have discovered a potential new target in the fight against colorectal cancer, the nation’s third most common malignancy and, next to lung cancer, the second leading cancer killer. Read More

Vanderbilt researchers found that chronic use of opioid painkillers like hydrocodone and oxycodone significantly increases the risk of dysphagia, or difficulty swallowing. Read More

A collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine. The group used multiple single-cell technologies, unbiased machine learning and traditional immunological approaches to track cellular and antibody responses in samples collected over time from a cohort of healthy participants. Read More

An international team that included researchers from Vanderbilt University Medical Center has discovered a molecular switch that induces rapid proliferation of zymogen granule-secreting chief cells in the stomach to regenerate damaged tissue. Read More

A team led by Vanderbilt researchers has described and characterized the first zinc metallochaperone: a protein that puts zinc into other “client” proteins. Read More

Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity. Read More

Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by C. Buddy Creech, MD, MPH, has found. Read More

Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.   Read More

Vanderbilt researchers are studying a bacterial pathogen that can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections. Read More

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations. Read More

Vanderbilt researchers have identified a critical regulatory factor in the bacterium that causes the disease anthrax and has been used as a biological weapon. Read More

Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19. Read More